General Overview
Eli Lilly has officially launched Foundayo (orforglipron), a pioneering once-daily oral GLP-1 receptor agonist, in the United Kingdom. This launch is significant as the UK is the first country in Europe to make this treatment available for weight management and Type 2 diabetes. Unlike traditional GLP-1 therapies (like Wegovy or Mounjaro) which require subcutaneous injections, Foundayo offers the convenience of a tablet form without strict food or water restrictions.
Foundayo: Drug Profile & Facts
How it Works: Mechanism of Action
For pharmacy students, understanding the MOA is crucial. Orforglipron acts as a potent agonist at the GLP-1 receptors, mimicking the natural hormone released after food intake. It effectively:
- Increases Satiety: Enhances the feeling of fullness.
- Suppresses Appetite: Reduces hunger and specific food cravings.
- Glycaemic Control: Improves blood glucose regulation in Type 2 diabetic patients.
- Weight Reduction: Supports significant loss of adipose tissue through reduced caloric intake.
Approved Dosage & Titration Schedule
To minimize gastrointestinal side effects and improve patient tolerability, Foundayo follows a strict dose escalation schedule. Pharmacy professionals should ensure patients understand that each increase only occurs after at least 30 days.
Clinical Efficacy: ATTAIN-1 Phase 3 Trial
The ATTAIN-1 Phase 3 trial demonstrated the clinical potency of oral orforglipron. Participants receiving the maximum dose achieved an average weight reduction of 12.4% (approx. 27.3 lbs), significantly higher than the 0.9% seen in the placebo group.
Who Can Use Foundayo? (Eligibility Criteria)
Foundayo is authorized in the UK as an adjunct to a reduced-calorie diet and increased physical activity for adults meeting the following BMI criteria:
Safety & Adverse Effects
Common side effects reported to the MHRA are primarily gastrointestinal. Pharmacists should counsel patients on managing these during the titration phase:
- Nausea & Vomiting
- Diarrhoea or Constipation
- Dyspepsia (Indigestion)
- Abdominal Pain
Pricing and Availability
Currently, Foundayo is not available on the NHS. It is undergoing assessment by NICE for potential routine access. For now, it is available via private prescription only.
Important Safety Message
Foundayo is a prescription-only medicine (POM). The MHRA warns against purchasing GLP-1 medications from unregulated or unauthorized online sellers. Pharmacy students should emphasize the importance of medicine authentication and professional supervision to patients.
